A new threat to Merck’s blockbuster cancer treatment, Moderna’s cutbacks, and obesity drugs for kids
What’s next for Akeso and Summit Therapeutics after their cancer immunotherapy outperformed Merck’s Keytruda in…
Category: The Readout LOUD
Summit’s upcoming cancer results, Recursion’s mixed data, and the next big obesity target
How effective is Summit Therapeutics’ lung cancer immunotherapy? Why are obesity drugmakers turning back to…
Jim Wilson’s next venture, a surprise startup shutdown, & Lilly’s Zepbound strategy
What’s behind the “great abandonment” in gene therapy R&D? How does a startup spend $213…
Listen: BioMarin’s executive shakeup, a GLP-1 lowers diabetes risk, and a deep look at Recursion’s AI bona fides
What does the hiring of a well-known industry dealmaker mean for the future of BioMarin…
Listen: Drug pricing drops & psychedelics under fire
Are pharma companies still fearful of the Inflation Reduction Act? Will Lykos’ FDA rejection and…
Listen: VC struggles, drug pricing negotiations, & Novo’s abrupt Wegovy decision
Why did Novo Nordisk pull its paperwork to expand the use of Wegovy for a…
Listen: The long journey to make malaria vaccines, and Sarepta’s ties with patient advocates
Why has it taken so long for the world to get malaria vaccines? What relationship…
Listen: UnitedHealth’s doctor empire, an FDA departure, and Viking’s obesity moves
What makes UnitedHealth similar to Standard Oil? Is Viking Therapeutics an attractive acquisition target? And…
Listen: JD Vance’s biotech ties, Cassava resignations, and insulin shortages
What relation does JD Vance have with Vivek Ramaswamy? Do pharma companies have a moral…
Listen: Biotech layoffs, founder-focused VC, & a big pharma exit
Why are pharmaceutical companies cutting more staff than cash-strapped biotechs? And who will Pfizer scout…
Listen: Medicare coverage for GLP-1 drugs, AI, and health care at the presidential debate
Will Medicare finally begin covering weight loss drugs like Zepbound and Wegovy? And what health…
Listen: Fauci’s memoir, Alnylam’s tenuous trial, and a mid-year review
Can Alnylam find success with its latest cardiac treatment after tweaking the trial? And did…
Listen: Duchenne gene therapy setback, Alzheimer’s drug endorsement & why a STAT reporter buys weed (for journalism)
On this week’s episode of “The Readout LOUD,” our STAT colleague Nicholas Florko joins us…
Listen: Psychedelics at the FDA, ASCO recap, & MorphoSys update
How did advisers react to the first psychedelic therapy to go before the Food and…
Listen: An ASCO preview & another Duchenne trial failure
Which presentations are worth catching at ASCO this weekend? What is exon-skipping? And how do…
Listen: More tumult at BIO & coercive care for sickle cell patients
How does a drug industry lobbying group move forward after years of upheaval, including having…
Listen: Live! From the STAT Breakthrough Summit West
On this week’s “Readout LOUD,” we’re live in San Francisco at STAT’s Breakthrough Summit West….
Listen: Everything you need to know about H5N1 bird flu
What happens when a common virus jumps from birds to cows? And should we be…
Listen: Controversial brain tissue research, obesity drug sales, and Novartis’ M&A drama
The removal of small amounts of brain tissue from desperately ill patients, done as part…
Listen: A new obesity startup, an acquisition gone wrong, & the future of Teledoc
How does a startup compete with the likes of Eli Lilly and Novo Nordisk in…
Listen: Vertex’s big deal, biotech’s red numbers, & an industry history lesson
How would you spend $13 billion in cash? Is biotech stale? And remember Dendreon? We…
Listen: Biotech mega-rounds, a cancer vaccine setback & CEOs keep their promise
Why is it surprising when drug executives stay true to their word? And can neoantigen…
Listen: What the mifepristone case means, GLP-1 skepticism, & Chinese biotech
Who gets to sue the FDA? Is pharma caught in a trade war? And what…
Listen: Live! From the STAT Breakthrough Summit East
Is there a cure for allergies? Has the FDA become too flexible? And which drugs…
Listen: A dilemma in ALS, the first MASH drug, & why gene therapy is hard
What happens when an approved drug doesn’t work? Why don’t patients want gene therapy? And…
Listen: VC turmoil, GLP-1 competition, & the war on recovery
Why are addiction treatments so hard to get? Can small companies compete in obesity? And…
Listen: Legal insider trading, booming biotech stocks, & the next GLP-1
Are biotech’s dog days over? What’s a PIPE? And what can unseat Wegovy? We cover…
Humira’s legacy, CEO symbolism, and genomic surgery
What do CEOs owe the world? Did Humira break the system? And can you CRISPR…
Listen: Pharma goes to Washington, Alnylam’s future, & Gilead’s dealmaking
Has PhRMA lost its fangs? Are 11th-hour changes ominous for clinical trials? And what’s next…
AI in medicine, detangling hype, and Icelandic DNA
Has AI really solved biology? What can machines teach us about medicine? And what’s a…
Listen: Vertex’s polarizing data, Aduhelm’s adieu, & an FDA icon
What makes a blockbuster? Can biotech learn from Aduhelm? And how do you replace a…
Listen: The plight of the VC, Gilead’s latest setback, & more M&A
Are venture capitalists OK? Are bolt-ons good for business? And when is it safe to…
Biotech layoffs, slumping stocks, and a 2024 preview
Why are rich biotechs cutting costs? Has JPM Week already worn off? And what’s going…
Listen: Live! From JPM 2024
Is biotech back from its downturn? Can Nvidia solve biology? And is it wise to…
Listen: 2023 in review, CEO report cards, and a look at the year ahead
What does it mean to a bad CEO? Can biotech endure another election year? And…
Listen: FTC v. biotech, Pfizer’s kitchen sink, & Vertex’s future
Is no one safe from the FTC? Has Pfizer bottomed out? And is biotech finally…
CRISPR history, biotech struggles, & a big week for deals
How does the first CRISPR treatment work? Can biotech rebound? And when is $300 million…
AbbVie’s big deal, CAR-T’s risks, & getting a biotech job
Are ADCs having a moment? Is CAR-T safe? And who’s to blame for failed trials?…
Listen: A CRISPR milestone, algorithms amok, & biotech mixology
Who polices algorithms? How would you name the first approved CRISPR medicine? And what pairs…
Listen: Lilly’s obesity drug, the power of radiation, & a biotech implosion
What’s a radiopharmaceutical? What does it mean to be Zepbound? And who’s to blame for…
Listen: Decoding biotech hype, the Sarepta saga, & au revoir to a CEO
When is a failure not a failure? Does the FDA have special rules for Sarepta…
Listen: ESMO highlights, Roivant’s big deal, & biotech VC on the rise
How do cancer drugs work? What makes biotech stocks go up? And why are venture…
Listen: Live from the 2023 STAT Summit
What if CRISPR isn’t all that commercial? How does the NurOwn story end? And how…
Listen: Merger Mondays, Ozempic panic, & CRISPR’d pigs
When is a billion-dollar deal a bad omen? Has Wall Street gone overboard on Ozempic?…
Listen: Who discovered GLP-1? Plus: BrainStorm at the FDA and biotech’s slump
When is negative data positive enough? Who gets credit for scientific breakthroughs? And wasn’t biotech…
A thorny ALS debate at the FDA, and the promise of artificial wombs
Can the FDA be too flexible? How do you test a mechanical womb? And who…
Listen: Covid’s latest surge, Alnylam at the FDA, & the end of an era
What does Covid-19 have in store for the winter? When are good data not good…
Back to school for biotech, Biogen’s potential pivot, & Illumina’s next chapter
Are there still too many biotech companies? How do you know when you’re in a…
Listen: Vivek’s star turn, leaky drug data, & biotech as family business
Does biotech prepare you for the presidency? Who really wants to gut the FDA? And…
Listen: Racing for gene therapy, a pioneering approval, & startups in the lurch
What difference does a day make? Who gets to have gene therapy? And are biotech…